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Abstract
The epidermal growth factor receptor (EGFR) has been targeted for inhibition using tyrosine kinase inhibitors and
monoclonal antibodies, with improvement in outcome in subsets of patients with head and neck, lung, and colo-
rectal carcinomas. We have previously found that EGFR stability plays a key role in cell survival after chemotherapy
and radiotherapy. Heat shock protein 90 (HSP90) is known to stabilize mutant EGFR and ErbB2, but its role in
cancers with wild-type (WT) WT-EGFR is unclear. In this report, we demonstrate that fully mature, membrane-
bound WT-EGFR interacts with HSP90 independent of ErbB2. Further, the HSP90 inhibitors geldanamycin (GA)
and AT13387 cause a decrease in WT-EGFR in cultured head and neck cancer cells. This decrease results from
a significantly reduced half-life of WT-EGFR. WT-EGFR was also lost in head and neck xenograft specimens after
treatment with AT13387 under conditions that inhibited tumor growth and prolonged survival of the mice. Our
findings demonstrate that WT-EGFR is a client protein of HSP90 and that their interaction is critical for maintaining
both the stability of the receptor as well as the growth of EGFR-dependent cancers. Furthermore, these findings
support the search for specific agents that disrupt HSP90’s ability to act as an EGFR chaperone.
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Introduction
Several common epithelial cancers are driven by epidermal growth
factor receptor (EGFR)–mediated signaling. In the past decade, numer-
ous agents that inhibit EGFR activity have been developed and been
the subjects of rigorous preclinical and clinical studies. Recent studies
have suggested that therapy-induced degradation of EGFR, not its
inhibition, may correlate better with clinical outcome [1–9]. Although
ligand-induced, ubiquitin-mediated changes in EGFR trafficking and
degradation have been well studied in normal cells [10–12], little is
known about how EGFR protein stability is regulated in tumor cells.
We believe that a precise understanding of the regulation of EGFR pro-
tein stability will be useful in developing new classes of therapeutic
agents that can promote tumor-specific degradation of EGFR indepen-
dent of its kinase activity.
Abbreviations: CHX, cycloheximide; GA, geldanamycin; EGFR, epidermal growth
factor receptor; HSP90, heat shock protein 90; WT, wild-type
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Heat shock protein 90 (HSP90) is a molecular chaperone that is
known to regulate stability of various oncogenic kinases [13,14], espe-
cially under proteotoxic stress. HSP90 has been implicated in the
stability of ErbB2 and tyrosine kinase inhibitor (TKI)–resistant (T790M
EGFR), –truncated (EGFRvIII ), or –nascent EGFR [15–17]. Whereas
nascent and mutated EGFR have been shown to be HSP90 clients, con-
clusive evidence is still lacking regarding whether mature, wild-type (WT)
EGFR is an HSP90 client, particularly under conditions in which EGFR
is overexpressed.
We hypothesized that, in head and neck cancers where WT-EGFR
is often overexpressed, HSP90 interaction promotes receptor stability
and cell survival. Therefore, we carried out experiments to determine
whether mature plasma membrane–bound WT-EGFR binds to
HSP90 and to assess whether this interaction was direct or was
mediated by ErbB2. When we found a direct interaction between
mature EGFR and HSP90, we determined how inhibition of HSP90
activity affected the half-life of WT-EGFR. We then assessed the effect
of HSP90 inhibition by AT13387 on EGFR stability and tumor
growth in UMSCC1 head and neck xenografts. Our findings support
clinical investigation of HSP90 inhibitors in cancers overexpressing
WT as well as mutant EGFR and motivate studies to identify site(s)
by which EGFR and HSP90 interact as a specific way to promote
EGFR degradation and decrease cancer cell survival.
Materials and Methods
Reagents
AT13387 compound was provided by Astex Pharmaceuticals
(Cambridge, United Kingdom) through a Materials Transfer Agree-
ment with the National Cancer Institute (NCI, Bethesda, MD).
Geldanamycin (GA) was acquired from Assay Designs (Ann Arbor,
MI). EGFR (sc-03) antibody was acquired from Santa Cruz Biotech-
nology (Santa Cruz, CA). Antibodies for EGFR (D38B1), ErbB2,
GAPDH, HSP70, and cleaved poly (ADP-ribose) polymerase were
purchased from Cell Signaling (Danvers, MA), whereas antibodies to
detect ErbB2 were purchased from Neomarkers (Kalamazoo, MI).
Another EGFR antibody (31G7) was purchased from Invitrogen
(Grand Island, NY). Antibody against HSP90 was purchased from
Pharmingen (San Diego, CA). Cycloheximide (CHX) and FLAG
(M2) antibody were obtained from Sigma-Aldrich (St Louis, MO).
For immunofluorescence, HSP90 antibody from Enzo Life Sciences,
Inc (Farmingdale, NY) was used. The FLAG-Tagged HSP90 construct
was a gift from L. Neckers (NCI).
Cell Culture
The human head and neck squamous cell carcinoma (HNSCC)
cell lines UMSCC1, 11B, 12, 17B, 29, 33, and 74B were kindly pro-
vided by Dr Thomas Carey (University of Michigan, Ann Arbor, MI).
The lung cancer cell line NCI-H1975 was provided by J. Engelman
(Massachusetts General Hospital, Boston, MA). BT474, SW620,
and Chinese hamster ovary (CHO) cells were purchased from the
American Type Culture Collection (Manassas, VA). All cell lines
were grown in RPMI 1640 supplemented with 10% cosmic calf
serum. For all in vitro experiments, cells were released from flasks
using phosphate-buffered saline (PBS) containing 0.01% trypsin
and 0.20 mM EDTA, and cells were plated onto culture dishes 2 days
before treatment.
Immunoblot Analysis
Cells were scraped into PBS-containing sodium orthovanadate
and protease inhibitor cocktail (Roche Diagnostic Co, Indianapolis,
IN). Cells were incubated for 15 minutes on ice in Laemmli buffer
(63 mM Tris-HCl, 2% [wt/vol] SDS, 10% [vol/vol] glycerol, and
0.005% [wt/vol] bromophenol blue) containing 100 mM NaF,
1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and 1 μg/ml
aprotinin. After sonication, cell lysates were clarified by centrifugation
at 13,000 rpm for 5 minutes at 4°C. The soluble protein fraction was
heated to 95°C for 5 minutes, applied to a 4% to 12% bis-tris precast
gel (Invitrogen), and transferred onto a polyvinylidene difluoride
membrane. Membranes were incubated for 1 hour at room tempera-
ture in blocking buffer consisting of 3% bovine serum albumin and 1%
normal goat serum in Tris-buffered saline (137 mM NaCl, 20 mM
Tris-HCl [pH 7.6], and 0.1% [vol/vol] Tween 20). Membranes were
subsequently incubated overnight at 4°C with 1 μg/ml primary anti-
body in blocking buffer, washed, and incubated for 1 hour with horse-
radish peroxidase–conjugated secondary antibody (Cell Signaling).
After three additional washes in Tris-buffered saline, the bound anti-
body was detected by enhanced chemiluminescence plus reagent
(Amersham Biosciences, Piscataway, NJ). For quantification of relative
protein levels, immunoblot films were scanned and analyzed using
ImageJ 1.46m software (National Institutes of Health, Bethesda, MD).
Unless otherwise indicated, the relative protein levels shown represent a
comparison to untreated controls.
Immunoprecipitation
Cells were trypsinized, washed twice with PBS, and cell lysates were
prepared by incubation for 30 minutes on ice in fresh lysis buffer (1%
Triton X-100, 0.1% sodium dodecyl sulfate, 0.15 M sodium chloride,
0.01 M sodium phosphate, pH 7.2 1 mM phenylmethylsulfonyl
fluoride, 2 μg/ml aprotinin, 0.2 mM sodium orthovanadate, 50 mM
sodium fluoride, 2mMEDTA,20mMammoniummolybdate). Immuno-
precipitation of EGFR and HSP90 was performed as described previ-
ously [18]. For subcellular fractionation studies, cytosolic, nuclear,
and membrane fractions were isolated using a Compartment Protein
Extraction Kit (Millipore, Billerica, MA). The purity of fraction in
the input was confirmed by immunoblot analysis with HSP90 (cyto-
sol), EGFR (membrane), and poly (ADP-ribose) polymerase (nucleus).
The extracts from these fractions were subjected to immunoprecipita-
tion (IP), and the interaction between EGFR and HSP90 was assessed
by immunoblot analysis.
Immunostaining
The Tissue and Histology Core of the Comprehensive Cancer
Center and the Pathology Core for Animal Research in the Unit for
Laboratory Animal Medicine at the University of Michigan provided
assistance in preparing specimens for immunohistochemistry. After
slides were deparaffinized in xylene and rehydrated using serial etha-
nol dilutions, antigen site unmasking was performed by immersing
slides in citrate buffer for 20 minutes at high pressure and temperature
inside a pressure cooker. Slides were then washed in PBS, blocked for
1 hour, and incubated in primary antibody at 4°C overnight. Slides
were then washed again in PBS, incubated in secondary antibody for
1 hour, rewashed, and prepared with a coverslip after a drop of Pro-
Long Gold antifade reagent with 4′,6-diamidino-2-phenylindole
(Molecular Probes) was added to each sample. Fluorescence images
were acquired using DS-Fi1 (Nikon, Melville, NY) camera fitted
on an Olympus 1X-71 microscope. For costaining, cells were grown
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on coverslips and fixed with paraformaldehyde. The coverslips were
blocked and incubated with antibodies to EGFR and HSP90 over-
night. The coverslips were processed as described above.
GST EGFR-HSP90 Direct Interaction Assay
PurifiedGST-EGFR (His672-Ala1210, 90 kDa, 1 μg) fusion protein
(Cell Signaling) was incubated with 50 μl (3.5 mg swelled in deionized
water) of glutathione agarose beads (Sigma-Aldrich) equilibrated in
0.5× Superdex buffer (1× Superdex buffer: 25 mM HEPES, pH 7.5,
12.5 mM MgCl2, 10 μM ZnSO4, 150 mM KCl, 20% glycerol, 0.1%
Nonidet P-40, and 1 mM EDTA) for 2 hours at 4°C and then washed
three times with 0.5× Superdex buffer. Two hundred nanograms of
purified HSP90 protein (Assay Designs) was then added to the washed
beads and incubated overnight at 4°C. The beads were washed three
times using 0.5× Superdex buffer and boiled in Laemmli buffer, and
the bound HSP90-EGFR complex was detected by immunoblot anal-
ysis with HSP90- and EGFR-specific antibodies.
Half-life Studies of EGFR
UMSCC1 cells were treated with vehicle or AT13387 (30 nM) for
12 hours followed by CHX (100 μg/ml). Cells were then harvested at
different time points (0-15 hours). The effect of HSP90 inhibition
Figure 1. Interaction of WT-EGFR with HSP90. Immunoprecipitation using anti-HSP90 antibody revealed minimum EGFR in the complex;
therefore, ammonium molybdate (20 mM), which is known to stabilize the interaction of HSP90 with its client proteins, was added to the
lysis buffer. (A) IP results showed an increase in EGFR-HSP90 interaction with increasing concentrations of ammonium molybdate.
Densitometric analysis of the films was performed using ImageJ software, and relative intensity is shown. Two EGFR antibodies were
used to confirm these results. (B) Interaction between HSP90 and EGFR was assessed in five cell lines, representing normal EGFR-
expressing cells (MRC5), EGFR-negative (SW620), ErbB2-driven, EGFR-independent (BT474), erlotinib-resistant (T790M-EGFR; NCI-
H1975), and EGFR-amplified (UMSCC1) tumor cells. To address the issue of cross-reactivity, multiple EGFR antibodies were used,
and their pattern was compared with ErbB2. One EGFR and one ErbB2 antibody were selected for the IP experiments. UMSCC1 and
NCI-H1975 cell lines showed maximum interaction between EGFR with HSP90, whereas BT474 and MRC5 cells showed minimal inter-
action. EGFR-HSP90 interaction was absent in EGFR null SW620 cells. Colocalization of EGFR and HSP90 in tumor cells, xenografts,
head and neck cancer patient’s tumor was assessed by dual immunostaining for EGFR and HSP90. (C) UMSCC1 cells showed modest
colocalization of these two proteins, which was also confirmed in (D) xenograft and (E) patient tumor specimen.
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on EGFR half-life was assessed using immunoblot analysis with the
anti-EGFR antibody.
Animal Studies
Immunodeficient BALB/c SCID mice were injected subcutane-
ously on the right flank with 5 × 106 UMSCC1 cells. Once tumors
were palpable, animals were randomized into treatment groups.
AT13387 (55 mg/kg for two consecutive days; Monday and Tuesday
weekly) suspended in cyclodextrin was administered through intra-
peritoneal injections [19,20]. Tumor size was measured three times
per week, and tumor volumes were calculated as follows: volume
(cm3) = (L × W 2) / 2. Two vehicle and three AT13387-treated mice
were euthanized on day 16, tumors were harvested, and the effect of
AT13387 on EGFR, ErbB2, and HSP70 was analyzed by immuno-
blot analysis.
Head and Neck Tumor Biopsy
The patient biopsy was obtained from a newly diagnosed pathology-
proven locally advanced head and neck squamous cell carcinoma. At the
time of this biopsy, the patient had not undergone any chemotherapy
or radiation therapy. The tissue was fixed in formalin and processed
for immunostaining.
Results
WT-EGFR Interacts with HSP90 in Cell Lines and
Head and Neck Tumors
In our pilot experiments using standard conditions [21], we found
that only a small amount of EGFR was immunoadsorbed by HSP90
antibody (Figure W1, first lane). We hypothesized that this could
be due to the dynamic nature of EGFR-HSP90 interaction and that
stabilization of this complex would increase the amount of EGFR
that would be immunoadsorbed with HSP90. Therefore, we used
ammonium molybdate, which is known to stabilize HSP90 clients
[22], in the lysis buffer and found approximately a three-fold increase
in immunoadsorbed full-length mature EGFR (Figures 1A and
W1). We next determined the specificity of this interaction with
HSP90 using multiple cell lines, chosen to represent various forms
of EGFR or ErbB2, such as UMSCC1 (amplified EGFR), NCI-
H1975 (erlotinib-resistant T790M-mutated EGFR), SW620 (EGFR
null), BT474 (ErbB2-overexpressing, EGFR-independent), and nor-
mal lung fibroblast MRC5 (normal expression of WT-EGFR). We
found a substantial interaction between EGFR and HSP90 in
UMSCC1 and NCI-H1975 tumor cells, no interaction with SW620
(null) cells, and little interaction in MRC5 cells and BT474 cells
(Figure 1B). We assessed the relative expression of EGFR and ErbB2
in these cell lines using several antibodies against EGFR to ensure that
this interaction was not due to a cross-reactivity of EGFR antibodies to
ErbB2. Next, we confirmed the specificity of interaction in six other
HNSCC cell lines (UMSCC11B, 12, 17B, 29, 33, and 74B) by
performing IP using not only HSP90 but also EGFR antibody
(Figure W2). We extended the immunoadsorption studies further to
assess if EGFR were colocalized with HSP90 in tumor cells, xenografts,
and HNSCC patient tumors, which are known to overexpress EGFR.
We observed modest costaining of HSP90 and EGFR in all the tissues
(Figure 1, C-E ). Overall, these data indicate that WT and fully mature
EGFR do interact with HSP90 especially under conditions of EGFR
overexpression and that the colocalization is only modest under less
stressful (untreated) conditions, which suggests a potential role of
HSP90 in WT-EGFR protein stability.
Mature EGFR Physically Interacts with HSP90
As the HSP90-bound EGFR had an apparent size of 170 kDa,
which is the size of the membrane-bound mature form, we wished
to determine whether the HSP90-EGFR interaction occurs in the cell
membrane. For this analysis, subcellular cytosolic, nuclear, and mem-
brane fractions were isolated from UMSCC1 cells, and EGFR-bound
Figure 2. Localization, specificity, and nature of EGFR and HSP90 interaction. (A) To analyze whether the mature form of EGFR interacts
with HSP90, subcellular fractionation followed by IP was carried out in UMSCC1 cells. EGFR-HSP90 interaction was confirmed in
cytosolic, nuclear, and membrane fractions of UMSCC1 cells. (B) The specificity of this interaction was confirmed by expression of
FLAG-tagged HSP90 in UMSCC11B cells, incubated with or without GA or (C) full-length EGFR in EGFR-negative CHO cells. (D) Direct
interaction between EGFR and HSP90 was confirmed in vitro by GST pull-down assay.
Neoplasia Vol. 14, No. 8, 2012 Stabilization of EGFR by HSP90 Ahsan et al. 673
HSP90 was resolved. We found that both cytosolic (nascent) and
membrane-bound (mature) forms of EGFR interact with HSP90
(Figure 2A ). The specificity of this interaction was further confirmed
by expression of FLAG-tagged HSP90 in UMSCC11B cells followed
by IP using anti-FLAG antibody (Figure 2B ). HSP90 inhibition by
GA reduced this interaction, indicating that HSP90 activity might be
necessary for its interaction with EGFR.
Because both EGFR and HSP90 are known to interact directly
with ErbB2 [23,24], we wished to rule out the possibility that the
interaction between EGFR and HSP90 is through ErbB2. Therefore,
we carried out experiments using CHO cells, which are both EGFR-
and ErbB2-negative [6]. In this case, wewere able to immunoprecipitate
ectopically expressed WT-EGFR using anti-HSP90 antibody, suggest-
ing that this interaction is not mediated by ErbB2 (Figure 2C ).We also
confirmed that this interaction was not mediated through Src or AKT
(data not shown). To further assess if this interaction were direct, we
performed in vitro GST pull-down assays using GST-EGFR and
HSP90protein. The complexwas detected by immunoblot analysis sug-
gestive of a direct interaction between EGFR and HSP90 (Figure 2D).
Overall, these results show that the stability of oncogenic WT-EGFR
may depend on its interaction withHSP90, that this interaction is direct
and not mediated by heterodimerization of EGFRwith ErbB2, and that
the EGFR-HSP90 interaction is enhanced in tumor compared with
normal cells.
HSP90 Inhibition Degrades WT-EGFR
The interaction of HSP90 with EGFR has been thought to be lim-
ited to nascent protein under conditions of normal EGFR expression
[17,21]. To investigate the effect of HSP90 inhibition on mature WT-
EGFR in cells overexpressing EGFR, we selected two head and neck
cancer cell lines that express relatively similar amounts of ErbB2
(known to be an HSP90 client [25]) and WT-EGFR (UMSCC1
and UMSCC29) and assessed the effect of two HSP90 inhibitors (GA
and AT13387) on EGFR protein levels relative to ErbB2. Both GA and
AT13387 induced EGFR and ErbB2 degradation in a concentration-
dependent manner (Figure 3). Notably, the rates of decrease in EGFR
and ErbB2 levels were comparable, indicating that the stabilities of both
are HSP90 dependent. Furthermore, both GA and AT13387 treatment
led to compensatory increases in HSP70 levels, indicative of inhibition
of HSP90 activity [26]. These results support that WT-EGFR is also
a HSP90 client, and inhibition of HSP90 activity induces comparable
degrees of EGFR and ErbB2 degradation.
If WT-EGFR were a client of HSP90, we would expect that inhibi-
tion of HSP90 activity would reduce the stability of EGFR. To analyze
the effect of HSP90 inhibition on EGFR stability, UMSCC1 cells were
treated with AT13387 (30 nM) for 12 hours, followed by 100 μg/ml of
CHX to block new protein synthesis. The combination of AT13387
and CHX was compared with CHX alone at several time points to
assess the rate of EGFR loss. The combination of AT13387 and
CHX reduced the half-life of EGFR to less than 4 hours compared with
8 hours withoutHSP90 inhibition. These results indicate that inhibition
of HSP90 activity by AT13387 accelerated the loss of EGFR (Figure 4).
In Vivo Effects of HSP90 Inhibition on HNSCC Tumors
Driven by WT-EGFR
If the direct interaction between HSP90 and WT-EGFR were im-
portant for the tumors driven by WT-EGFR, inhibition of this inter-
action would be expected to slow tumor growth. Therefore, we
treated UMSCC1 tumor-bearing mice with AT13387. The 3-week
treatment produced significant tumor growth delay (Figure 5A ) and
prolonged survival of mice (Figure 5B). To see if tumor growth delay
induced by AT13387 treatment had any effect on EGFR protein level,
three tumors were removed 24 hours after the last AT13387 injection
(day 16 from the initiation of treatment), and the relative EGFR expres-
sion was assessed by immunoblot analysis and immunostaining. Similar
to our in vitro observations (Figure 3), we found that inhibition of
Figure 3. Effects of HSP90 inhibition on WT-EGFR and ErbB2. To
assess EGFR degradation relative to ErbB2, UMSCC1, and
UMSCC29B cell lines harboring WT-EGFR were treated with either
GA (30 and 100 nM) or AT13387 (30 and 100 nM) for 12 hours.
Immunoblot analysis was carried out to detect the effect on EGFR
and ErbB2 levels. At 12 hours, loss of EGFR and ErbB2 in response
to GA or AT13387 was comparable.
Figure 4. Effects of HSP90 inhibition on EGFR stability. To assess
whether inhibition of HSP90 affects stability of EGFR, UMSCC1
cells were treated with AT13387 (30 nM) or DMSO for 12 hours,
followed by CHX (100 μg/ml) to block the new protein synthesis.
(A) The level of EGFR was assessed at multiple time points using
immunoblot analysis, and half-life was calculated. Inhibition of
HSP90 reduced the half-life of EGFR from 8 to 3.7 hours. (B) Rep-
resentative blots of EGFR are shown.
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HSP90 activity caused reduction of EGFR in UMSCC1 xenografts
(Figure 5, C and D).
Discussion
In this study, we have found that mature WT-EGFR interacts with
HSP90 in both tumor and normal cells. We detected this interaction
using immunoadsorption of endogenous or ectopically expressed
HSP90 or WT-EGFR and confirmed the direct interaction between
HSP90 and EGFR by in vitro GST pull-down experiment. The deg-
radation of EGFR on HSP90 inhibition is due to a decrease in the
protein stability of mature EGFR, indicating that WT-EGFR stability
is critically dependent on HSP90’s chaperone function. The finding
that HSP90 inhibition by AT13387 degrades EGFR and suppresses
growth of WT-EGFR–driven HNSCC tumors underscores the bio-
logic and potential clinical significance of these observations.
Although the major focus of research related to EGFR-targeted ther-
apy has been development of agents to block EGFR phosphorylation
[27], we and others have found that the physical presence of EGFR is
critical for cell survival. Small interfering RNA, chemotherapy- or
radiotherapy-induced degradation of EGFR causes cell death in
EGFR-driven tumor cells [1,3,5,6,28]. Blockade of HSP90 activity
is known to induce EGFR degradation in cells that harbor erlotinib-
resistant T790M or the ligand-independent truncated form of EGFR
(EGFRvIII) [16,17]. Overall, these results suggest that HSP90 inhibi-
tors may have a role in overcoming erlotinib resistance.
Although it is known that HSP90 inhibitors cause overall EGFR
levels to decrease over time [29], this has been attributed to an effect
only on the nascent EGFR, which is a client of HSP90 [30]. More
recently, the stability of mutant [15,16] and truncated forms of
EGFR (EGFRvIII) was shown to be regulated by HSP90 [17]. How-
ever, only minimal interactions between mature EGFR and HSP90
have been reported [31,32], and none of these reports has indicated
that WT-EGFR and HSP90 interact directly. This apparent lack of
interaction was unexpected because other EGFR family members
such as ErbB2 [32,33] and ErbB3 [34] are known to interact directly
with HSP90, and the stability of both nascent and mutant forms of
EGFR seems to depend on the HSP90 activity [17]. There are a
number of possible reasons why WT-EGFR and HSP90 interaction
was previously not detected. First, the studies that have investigated
the interaction between nascent EGFR and HSP90 have focused on
COS7 cells in an overexpression system [23,30]. It is possible that
tumor cells, which tend to contain much higher levels and a more
active form of HSP90, would be more likely to reveal HSP90-EGFR
binding. This may also explain why only a small amount of EGFR is
immunoadsorbed with HSP90 from MRC5 cells (normal fibroblasts),
which express only a moderate amount of EGFR. The second, and
Figure 5. Effect of HSP90 inhibitor AT13387 on UMSCC1 tumor growth. (A) SCID mice were inoculated on day 0 with UMSCC1 cells and
then randomized and treated on day 7. Mice received 55 mg/kg AT13387 dissolved in cyclodextrin solution or vehicle alone. Animals
were treated through the intraperitoneal route on two consecutive days per week (Monday and Tuesday, indicated by the arrows), for a
total of 3 weeks. Mice were euthanized when moribund beginning on day 18, as shown in B by the Kaplan-Meier plot. Student’s t test
revealed a significant difference (P< .05) in tumor volume between AT13387 treated and control animals during the treatment. (B) Effect
of AT13387 on the survival of mice. AT13387 treatment improved the survival of UMSCC1-bearing mice. (C) Vehicle- (n = 2) and
AT13387- (n = 3) treated mice were euthanized on day 16, tumors were harvested, and the effect of AT13387 on EGFR, ErbB2, and
HSP70 was analyzed by immunoblot analysis. (D) Effect on EGFR expression by AT13387 was further confirmed by immunostaining.
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perhaps more likely possibility, is related to the dynamic nature of the
interaction between EGFR and HSP90. At any given time, the amount
of EGFR interacting with HSP90 may be minimal compared with
other clients such as ErbB2, which is known to form a more stable
interaction with HSP90 [31]. Our data would be consistent with this
idea because stabilization of the HSP90 clients using ammonium
molybdate caused the amount of EGFR immunoadsorbed with
HSP90 to be enhanced several fold.
HSP90 expression in tumors is known to be elevated relative to
that in normal tissue [35,36]. We also observed a high expression of
HSP90 and EGFR in HNSCC patient tumor, similar to UMSCC1
xenografts (Figure 1E). This high expression of HSP90 in tumors most
likely provides stability to many oncogenic kinases that are either over-
expressed or activated through mutations. Previous studies have dem-
onstrated that only nascent or mutated EGFR binds to HSP90 [17],
but in this study using subcellular fractions, we found that not only the
cytoplasmic but also the membrane-bound mature EGFR coimmuno-
precipiates with HSP90 (Figure 2A). Treatment with HSP90 inhibitors
led to a rapid loss of total EGFR (Figures 3 and 4), indicating a critical
role of HSP90 in regulation of EGFR stability. These findings were
confirmed by a proof-of-principle in vivo therapy experiment where
inhibition of HSP90 activity by AT13387 treatment caused growth
delay of a WT-EGFR–driven head and neck carcinoma, which corre-
lated with a decreased expression of EGFR.
Our data confirm that blocking the chaperone function of HSP90
with HSP90 ATPase inhibitors, leading to EGFR degradation, is an
attractive approach for treatment of EGFR-dependent tumors. How-
ever, given the essential proteins for which HSP90 functions as a
chaperone [37], an approach targeting the specific interaction be-
tween EGFR and HSP90 could result in more selective cancer cell
killing. Although we have demonstrated that mature WT-EGFR is
an HSP90 client protein, the details of the interaction between
EGFR and HSP90 still need to be determined. Indeed, an in-depth
knowledge of HSP90 interaction with EGFR would provide an oppor-
tunity to develop an agent that would selectively disrupt EGFR-HSP90
interactions and cause EGFR degradation without affecting HSP90’s
other chaperone functions. The contact surface through which one
EGFR family member, ErbB2, interacts with HSP90 has been shown
to be in the M5 domain [32], which could be the starting point for
designing a more targeted approach to disrupt the interaction between
EGFR and HSP90. Studies focusing on identifying this region and
developing specific methods to block the interaction between EGFR
and HSP90 are currently underway in our laboratory.
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Figure W1. Effect of ammonium molybdate on the interaction of
mature WT-EGFR with HSP90. The effect of ammoniummolybdate
on the interaction between WT-EGFR and HSP90 was assessed by
IP as shown in Figure 1A. The full-length immunoblot shows an
increase in the interaction between mature EGFR (∼170 kDa) with
HSP90 with increasing concentrations of ammonium molybdate.
Figure W2. Specificity of immunoadsorption of EGFR and HSP90.
The specificity of antibody and the interaction between EGFR and
HSP90were confirmedby IPof EGFRorHSP90 followedby immuno-
blot analysis of HSP90 or EGFR, in six HNSCC cell lines. Both
approaches yielded relatively similar results, indicating the specificity
of protein-protein interaction.
